Fluicell AB (publ) (STO:FLUI)

Market Cap	10.99M
Revenue (ttm)	7.68M
Net Income (ttm)	-10.34M
Shares Out	1.37M
EPS (ttm)	-7.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,898
Average Volume	7,952
Open	7.75
Previous Close	7.70
Day's Range	7.55 - 8.00
52-Week Range	7.45 - 45.33
Beta	1.91
RSI	33.47
Earnings Date	Aug 15, 2025

About Fluicell AB

Fluicell AB (publ) operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology. The company offers BIOPEN, a microfluidic platform for high-precision single-cell solution delivery that enables to control the cell microenvironment without moving or disturbing the cells; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch-clam...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 12
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: FLUI

Financial Performance

In 2024, Fluicell AB's revenue was 5.35 million, an increase of 60.25% compared to the previous year's 3.34 million. Losses were -15.51 million, -41.59% less than in 2023.